+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07831902

RAINBO NSMP-ORANGE Trial Comparing Radiotherapy with Oral Progestin Tablets versus Radiotherapy and Chemotherapy in High-Risk NSMP Endometrial Cancer

Led by University College, London · Updated on 2026-09-21

600

Participants Needed

12

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying treatments for patients with high-risk No Specific Molecular Profile NSMP endometrial cancer to see if radiotherapy combined with oral progestin tablets can be as effective as the current standard treatment of radiotherapy with chemotherapy, while potentially causing fewer side effects and improving quality of life. This phase 3 trial compares these two approaches to refine adjuvant treatment based on molecular features. The study is sponsored by University College, London. Participants are randomly assigned to one of two groups. One group receives pelvic radiotherapy with or without vaginal brachytherapy followed by oral progestin tablets medroxyprogesterone acetate or megestrol acetate taken daily for 24 months. The other group receives pelvic radiotherapy with or without vaginal brachytherapy combined with chemotherapy drugs cisplatin, carboplatin, and paclitaxel, according to standard care. Treatments begin within 10 weeks after surgery. Participants undergo assessments for recurrence-free survival over 3 and 5 years, tracking cancer recurrence in various areas, survival rates, treatment-related toxicities, and quality of life using validated questionnaires. Imaging scans such as CT or PET-CT are used to confirm no distant metastases before enrollment. Treatment and follow-up are closely monitored to measure outcomes and safety through the study period ending in 2034.

CONDITIONS

Brief Title

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer

Research Team

R

RAINBO NSMP-ORANGE Trial Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here